Gilead Sciences (GILD) announced two key news items recently. It started off with positive proof of concept NASH results with a double combination treatment, which was presented at the International Liver Congress 2019. Then a few days later, it announced a partnership with Novo Nordisk (NVO) for the development of another NASH combination. While the latest results from the proof of concept are still in the early stages of clinical development, they do offer a lot of promise as the next trials begin.
Double Combination NASH Treatment
Gilead Sciences had a